Guru Murthy, G. S., Abaza, Y., Ball, S., Abboud, R., Haddadin, M., Feld, J., … Komrokji, R. (2025). Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes. In Blood (Vol. 146, pp. 239–239). American Society of Hematology. https://doi.org/10.1182/blood-2025-239

Guru Murthy, Guru Subramanian, Yasmin Abaza, Somedeb Ball, Ramzi Abboud, Michael Haddadin, Jonathan Feld, Suresh Kumar Balasubramanian, et al. “Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes.” In Blood, 146:239–239. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-239.

Guru Murthy GS, Abaza Y, Ball S, Abboud R, Haddadin M, Feld J, et al. Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes. In: Blood. American Society of Hematology; 2025. p. 239–239.

Guru Murthy, Guru Subramanian, et al. “Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 239–239. Crossref, doi:10.1182/blood-2025-239.

Guru Murthy GS, Abaza Y, Ball S, Abboud R, Haddadin M, Feld J, Balasubramanian SK, Kishtagari A, Cohen-Nowak A, Guerra V, Hawkins H, Shukla A, Tan V, Dulak D, Tawfiq R, Dworkin E, Weiss J, Feng A, Gonzalez-Lugo J, Dhakal P, Leonard J, Foucar C, Badar T, Shallis R, Im A, Patel S, Lin C, Patel A, Winer E, Atallah E, Komrokji R. Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes. Blood. American Society of Hematology; 2025. p. 239–239.